Abstract
A phase II programme was carried out in both Europe and North America to evaluate the activity of topotecan administered as a 21-day continuous intravenous infusion to patients with recurrent ovarian cancer. The European results are reported here. Patients who had failed first line therapy with a platinum-based regimen received topotecan 0.4 mg/m2/day, as a 21-day infusion every 28 days. Patients were only permitted one prior regimen. 35 patients were enrolled and evaluable for response. 3 patients (8.6%) had a partial response to treatment (95% CI 1.8%, 23.1%) with a median time to response of 8.1 weeks and a median duration of response of 17.6 weeks. Response was also evaluated by CA125 and was also found to be 8%. For all 35 patients, median time to progression was 16.1 weeks and median survival was 43.6 weeks. The principal toxicity was myelosuppression although grade 4 neutropenia occurred in only 8.8% of patients (2.1% of courses) and infectious complications were relatively infrequent. Non-haematological toxicity was generally mild and mainly consisted of gastrointestinal events, alopecia and fatigue. A prolonged infusion of topotecan was well tolerated with a low incidence of severe neutropenia. Responses were seen in both North American and European patients. Response rates varied between the 2 studies possibly due to differences in patient demographics. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: ovarian cancer, topotecan, continuous intravenous infusion
Full Text
The Full Text of this article is available as a PDF (48.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alberts D. S., Green S., Hannigan E. V., O'Toole R., Stock-Novack D., Anderson P., Surwit E. A., Malvlya V. K., Nahhas W. A., Jolles C. J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992 May;10(5):706–717. doi: 10.1200/JCO.1992.10.5.706. [DOI] [PubMed] [Google Scholar]
- Bookman M. A., Malmström H., Bolis G., Gordon A., Lissoni A., Krebs J. B., Fields S. Z. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998 Oct;16(10):3345–3352. doi: 10.1200/JCO.1998.16.10.3345. [DOI] [PubMed] [Google Scholar]
- Eisenhauer E. A., ten Bokkel Huinink W. W., Swenerton K. D., Gianni L., Myles J., van der Burg M. E., Kerr I., Vermorken J. B., Buser K., Colombo N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994 Dec;12(12):2654–2666. doi: 10.1200/JCO.1994.12.12.2654. [DOI] [PubMed] [Google Scholar]
- Hochster H., Liebes L., Speyer J., Sorich J., Taubes B., Oratz R., Wernz J., Chachoua A., Raphael B., Vinci R. Z. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol. 1994 Mar;12(3):553–559. doi: 10.1200/JCO.1994.12.3.553. [DOI] [PubMed] [Google Scholar]
- Hochster H., Wadler S., Runowicz C., Liebes L., Cohen H., Wallach R., Sorich J., Taubes B., Speyer J. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol. 1999 Aug;17(8):2553–2561. doi: 10.1200/JCO.1999.17.8.2553. [DOI] [PubMed] [Google Scholar]
- Lorigan P. C., Crosby T., Coleman R. E. Current drug treatment guidelines for epithelial ovarian cancer. Drugs. 1996 Apr;51(4):571–584. doi: 10.2165/00003495-199651040-00005. [DOI] [PubMed] [Google Scholar]
- Ozols R. F., Hamilton T. C., Hoskins W. J., Bast R. C., Jr, Young R. C. Summary of symposium: Biology and therapy of ovarian cancer. Semin Oncol. 1991 Jun;18(3):297–306. [PubMed] [Google Scholar]
- Rustin G. J., Nelstrop A. E., Bentzen S. M., Bond S. J., McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 2000 Apr;18(8):1733–1739. doi: 10.1200/JCO.2000.18.8.1733. [DOI] [PubMed] [Google Scholar]
- ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., Broom C., Scarabelli C., Davidson N., Spanczynski M. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun;15(6):2183–2193. doi: 10.1200/JCO.1997.15.6.2183. [DOI] [PubMed] [Google Scholar]